RedHill Biopharma Ltd. has announced its upcoming Annual General Meeting (AGM) to be held on September 17, 2024. The notice includes several key proposals for shareholder voting, including the reappointment of Kesselman & Kesselman as the company's auditors for 2024, the reelection of Eric Swenden and Ofer Tsimchi, and the election of Dr. Roni Mamluk to the Board of Directors for a three-year term. Additionally, the AGM will address the approval of restricted share units (RSUs) grants to non-executive directors, the company's CEO Dror Ben-Asher, and Chief Commercial Officer Rick D. Scruggs. Shareholders will also have the opportunity to review the company's financial statements for the fiscal year ended December 31, 2023. The meeting will take place at the company's offices in Tel Aviv, Israel, and shareholders of record as of August 6, 2024, are entitled to vote. The Board of Directors recommends voting in favor of all the proposals.

RedHill Biopharma Ltd. has announced its upcoming Annual General Meeting (AGM) to be held on September 17, 2024. The notice includes several key proposals for shareholder voting, including the reappointment of Kesselman & Kesselman as the company's auditors for 2024, the reelection of Eric Swenden and Ofer Tsimchi, and the election of Dr. Roni Mamluk to the Board of Directors for a three-year term. Additionally, the AGM will address the approval of restricted share units (RSUs) grants to non-executive directors, the company's CEO Dror Ben-Asher, and Chief Commercial Officer Rick D. Scruggs. Shareholders will also have the opportunity to review the company's financial statements for the fiscal year ended December 31, 2023. The meeting will take place at the company's offices in Tel Aviv, Israel, and shareholders of record as of August 6, 2024, are entitled to vote. The Board of Directors recommends voting in favor of all the proposals.